Achaogen Inc (NASDAQ:AKAO) – Stock analysts at William Blair reduced their Q1 2018 earnings per share (EPS) estimates for shares of Achaogen in a report issued on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will earn ($1.00) per share for the quarter, down from their prior forecast of ($0.73). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Achaogen’s Q2 2018 earnings at ($1.02) EPS, Q3 2018 earnings at ($0.94) EPS, Q4 2018 earnings at ($0.91) EPS, FY2018 earnings at ($3.87) EPS and FY2019 earnings at ($3.18) EPS.
Achaogen (NASDAQ:AKAO) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.21). Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%. The business had revenue of $1.87 million during the quarter, compared to analyst estimates of $1.18 million.
Other analysts also recently issued research reports about the company. Leerink Swann restated an “outperform” rating on shares of Achaogen in a report on Sunday. SunTrust Banks cut their price objective on Achaogen to $27.00 and set a “buy” rating on the stock in a report on Wednesday, January 3rd. Wedbush restated an “outperform” rating and set a $22.00 price objective (down previously from $28.00) on shares of Achaogen in a report on Wednesday, February 14th. Zacks Investment Research downgraded Achaogen from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Achaogen in a report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $24.10.
Shares of Achaogen (NASDAQ AKAO) opened at $11.00 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.83 and a quick ratio of 4.83. The firm has a market cap of $491.53, a PE ratio of -3.11 and a beta of 1.28. Achaogen has a 1-year low of $9.83 and a 1-year high of $27.79.
In other Achaogen news, major shareholder Robert W. Duggan bought 527,396 shares of the company’s stock in a transaction dated Friday, March 2nd. The shares were bought at an average price of $10.31 per share, for a total transaction of $5,437,452.76. Following the acquisition, the insider now directly owns 5,697,752 shares of the company’s stock, valued at $58,743,823.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Robert W. Duggan bought 95,012 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was acquired at an average price of $11.13 per share, for a total transaction of $1,057,483.56. Following the acquisition, the insider now directly owns 5,602,752 shares in the company, valued at $62,358,629.76. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 717,408 shares of company stock worth $7,557,386 and have sold 7,354 shares worth $78,467. 8.36% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of AKAO. MetLife Investment Advisors LLC acquired a new position in shares of Achaogen in the 4th quarter valued at about $151,000. Clear Harbor Asset Management LLC acquired a new position in shares of Achaogen in the 4th quarter valued at about $177,000. Ellington Management Group LLC acquired a new position in shares of Achaogen in the 4th quarter valued at about $177,000. Tower Research Capital LLC TRC increased its holdings in shares of Achaogen by 375.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 14,725 shares during the period. Finally, California Public Employees Retirement System acquired a new position in shares of Achaogen in the 2nd quarter valued at about $243,000. Institutional investors own 80.91% of the company’s stock.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).